Clinical Trials Logo

Pulmonary Disease, Chronic Obstructive clinical trials

View clinical trials related to Pulmonary Disease, Chronic Obstructive.

Filter by:

NCT ID: NCT03804138 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Immune Damage and Vaccination in COPD Patients

ALTIBPCO
Start date: October 9, 2018
Phase:
Study type: Observational

Better understanding of the specificities of the vaccine response in patients with COPD

NCT ID: NCT03802357 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Effects of Different Exercise Training Modalities in Alpha-1 Antitrypsin Deficiency Patients

Start date: January 10, 2019
Phase: N/A
Study type: Interventional

Pulmonary rehabilitation (PR) including exercise training is highly effective by improving health-related quality of life, exercise capacity and symptoms in patients with crhonic obstructive pulmonary disease (COPD). Therefore, PR is a main component in the management of COPD. In a former study patients with Alpha-1 Antitrypsin deficiency (A1ATD)-related COPD (genotype PiZZ) have been found to show smaller improvements in exercise capacity after a 3-week inpatient PR program compared to COPD patients without A1ATD (genotype PiMM)[1]. These between-group differences were mirrored by missing adaptations of the fatigue-resistant skeletal muscle fibre type I in A1ATD patients. This was in contrast to COPD patients without A1ATD who increased the proportion of this fibre type after PR. Myofibre type I is crucial because it enables patients for physical endurance activities (walking, cycling etc.) during their daily life. The aim of this study is to compare the effects of an exercise Training program with high vs. moderate Training intensity in order to find a Training modality which improves Training effects in A1ATD patients.

NCT ID: NCT03799354 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Study on Impact of Maximal Strength Training in Patients With COPD

Start date: January 15, 2019
Phase: N/A
Study type: Interventional

In the context of pulmonary rehabilitation of COPD patients, recent guidelines and metanalysis describe that Resistance Training (RT) can be successfully performed alone or in conjunction with Endurance Training (ET) without evidence of adverse events. Maximal Strength Training (MST) is a kind of RT typically performed at ~85-90% of 1RM with maximal velocity to be developed in the concentric phase. Recent literature indicates a significant amelioration on the Rate of Force Development (RFD) after MST in healthy subjects, post-menopausal woman and older populations. When comparing to the conventional ET, MST generates a little change in muscle mass (no hypertrophy), but a much greater improvement in the RFD. It has been described that neural adjustments play a major role in the MST-induced adaptations. MST is also well documented to improve aerobic endurance by improving walking work efficiency. Only a small cohort study of COPD patients was conducted, describing that MST can meaningfully improve strength and RFD, with an increase of around 32% for mechanical efficiency and a decrease of the perceived effort during submaximal job. This improvement could determine best performances in daily activities and a best quality of life. The main aims of this physiological pilot randomized controlled trail will be to evaluate feasibility and efficacy of the MST compared to standard ET on strength, effort tolerance, fatigue, economy of walking, dyspnea and risk of falls in a populations of COPD patients, in a short and middle term (6 months).

NCT ID: NCT03799263 Not yet recruiting - COPD Clinical Trials

A Six Minute Walking Test Based Index as an Outcome Predictor in COPD Subjects. (Chronic Obstructive Pulmonary Disease)

COPD
Start date: February 1, 2019
Phase:
Study type: Observational

The six minute walking test (6MWT) is a recognized clinical test to evaluate exercise capacity in different diseases and different conditions. The modalities of performance are described in International Guidelines. The usually reported measure is the distance in meters walked in 6 minutes. Despite the report of a single variable during the test is considered as a limit, changes in monitored variables are seldom analyzed together with the distance walked. In the past there have been some attempts of multifactorial evaluation of 6MWT, however up to date, there is no system considering together the changes of different variables. The investigators wonder whether a multidimensional index based on variables monitored during the 6MWT would better predict 24 month exacerbations and mortality in COPD patients.

NCT ID: NCT03797768 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Community-based Management of Chronic Obstructive Pulmonary Disease in Nepal

COBIN-P
Start date: March 1, 2019
Phase: N/A
Study type: Interventional

Chronic Obstructive Pulmonary Disease (COPD) is the fourth most important cause of death worldwide and is one of the commonest non-communicable diseases (NCDs) in Nepal. The presence of risk factors like indoor and outdoor air pollution, the high prevalence of smoking and lack of general awareness of COPD makes it a serious public health concern. However, no attempt has been made in Nepal to estimate its burden and address the disease at the community level. This community-based cluster randomized controlled study aims to fulfil that gap through mobilization of Female Community Health Workers (FCHVs) who will be trained to perform a certain set of health promotion activities aimed at prevention of the disease and its progression. Baseline and follow-up surveys will be conducted to compare the intervention and control groups. This study has the potential to generate evidence in helping address NCDs in Nepal and also other similar resource-limited countries.

NCT ID: NCT03796455 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Fish Oil and HMB Supplementation in COPD

COPD fish oil
Start date: April 25, 2018
Phase: N/A
Study type: Interventional

In the present study, the role of chronic (10 weeks) intake of low dose (2g/day) of EPA+DHA in whole body protein metabolism, and functional performance and systemic inflammation will be examined, and whether adding either HMB at 3.0 g/d to the low dose of EPA+DHA (2.0 g/d) will enhance these effects even more.

NCT ID: NCT03795350 Not yet recruiting - Asthma Clinical Trials

Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients

STORM
Start date: January 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the lung deposition and distribution pattern of TRIMBOW using a Gamma-scintigraphic technique after inhalation of a single dose of 99mTc radiolabelled TRIMBOW administered via pMDI in healthy volunteers, asthmatic and COPD patients

NCT ID: NCT03794583 Enrolling by invitation - Clinical trials for Chronic Obstructive Pulmonary Disease

Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

PERFECTOLE
Start date: December 21, 2018
Phase: Phase 3
Study type: Interventional

This open-label study will evaluate the safety of continued therapy with inhaled treprostinil in subjects who have completed Study RIN-PH-304. This study hypothesizes that long-term safety findings will be similar to those observed in the randomized, placebo-controlled, double-blind, adaptive study 'A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Chronic Obstructive Pulmonary Disease (PH-COPD)(RIN-PH-304).

NCT ID: NCT03794557 Recruiting - COPD Clinical Trials

The Effect of Inhaled PUL-042 on Rhinovirus-induced Symptoms in Smokers With GOLD Stage 0 COPD

Start date: January 2019
Phase: Phase 2
Study type: Interventional

This is a study examining the effect of inhaled PUL-042 on peak lower respiratory symptoms as measured by subject diary in early stage COPD subjects who are experimentally infected with rhinovirus. Subjects will receive 1 dose of PUL-042 followed by inoculation with HRV A16 virus 24 hours later. An additional dose of PUL-042 will be administered 48 hours post-inoculation. Subjects will be followed for 6 weeks post-inoculation

NCT ID: NCT03793192 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Promoting Activity After COPD Exacerbations, Aim 2

PACE2
Start date: January 2019
Phase: N/A
Study type: Interventional

This randomized controlled pilot study involving patients with chronic obstructive pulmonary disease (COPD) recently discharged from the hospital will evaluate the feasibility and efficacy of a home-based mobile-health supported physical activity promotion program.